UGT1A1 wild-type

We showed that the accumulation of UGT1A1 variants or the rarity of the variation is associated with a better prognosis, and the effect magnitude correlates with UGT1A1 deficiency. This study demonstrates the therapeutic potential of host UGT1A1 variations underlying GS against HBV infection outcomes.

P1/2, N=13, Active, not recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Dec 2023 --> Oct 2024

Significance Statement To our knowledge, this is the first study to characterize the enzymes responsible for each step of nintedanib metabolism in the human body. We found that β-glucuronidase may contribute to BIBF1202-G deglucuronidation.

P1/2, N=13, Active, not recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Completed --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2023

P3, N=608, Recruiting, National Cancer Center Hospital East

P1/2, N=13, Completed, Institut du Cancer de Montpellier - Val d'Aurelle | Active, not recruiting --> Completed

However, ≥grade 3 neutropenia was observed significantly more frequent in SH. It is necessary to pay attention to neutropenia when administering IRIS/Bev to patients with SH.

Further analysis is needed to investigate the impact of the UGT1A1 status on the treatment outcome of nal-IRI+5-FU/LV for patients with PDAC. These results were previously reported in the ESMO World Congress on Gastrointestinal Cancer 2022 (#SO-30).

P1/2, N=13, Active, not recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Recruiting --> Active, not recruiting | N=87 --> 13 | Trial completion date: Mar 2025 --> Oct 2022

IREC showed an objective response rate of 15% including 1 case with partial response. IREC was well tolerated regardless of UGT1A1 genotype. This study suggests that IREC is a promising second-line chemotherapy for refractory or relapsed neuroblastoma.

Chemotherapy based on high dose irinotecan improved the clinical efficacy in mCRC patients with UGT1A1*28 wild-type and heterozygous variant, and the toxicity was tolerated, as reflected in most studies. We are optimistic about the application of high dose irinotecan for mCRC patients with UGT1A1*28 wild-type or heterozygous variant, which will provide a relatively clear direction for future research and certain norms for clinical practice.

Irinotecan dose was selected according to the polymorphism of UGT1A1 gene, which was divided into 3 groups: UGT1A1*6 wild-type (GG type): 125mg/m2, d1, d8; UGT1A1*6 mutant heterozygosity (GA type) 100mg/m2, d1, d8; UGT1A1*6 homozygosity mutation (AA type) 75mg/m2, d1, d8 or paclitaxel 125mg/m2, d1, d8. UGT1A1*6 gene polymorphism was significantly associated with diarrhea and neutropenia induced by irinotecan. The safety and effectiveness of antitumor therapy might be significantly improved by individualized drug administration according to the results of UGT1A1*6 gene polymorphism.

P1/2, N=87, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Mar 2022 --> Mar 2025